2cureX AB (publ) (2CUREX) Earnings Call Transcripts

2cureX AB (publ)'s Latest Earnings Call - May 20, 2026

In the Q1 2026 earnings call, 2cureX AB (publ) emphasized its strategic shift towards becoming a comprehensive functional precision medicine platform. The company highlighted its partnership with StorMyTumor, which aims to enhance tumor preservation and testing capabilities, crucial for expanding its U.S. market presence. While specific revenue figures were not disclosed, management expressed optimism about future revenue streams from new collaborations and the introduction of devices in hospitals later this year, indicating a potential growth trajectory for the fiscal year.

Reported metrics

Guidance from management

Management expressed optimism about future revenue growth driven by new partnerships and the introduction of devices in hospitals, although specific financial guidance was not provided.

What management said

Hello, everybody. I hope you can hear me. There should be a chat box and Q&A. I think there are a few people still coming in. So we'll leave it for a few more seconds. [Operator Instructions] You'll probably notice that I'm listed here as being Galen Moore. I am not Galen Moore. I'm Nat. So sorry, we've had some technical issues at our end. We've got Ole on the call as well. Hi there, Ole, how are you?

And the short answer to that is yes. The storing of tissue as alluded to earlier, really leaves options for patients in the future. So yes, this is designed to be a recurring revenue stream.

What analysts pressed on

Analysts raised questions about competition and the potential impact of regulatory changes on market dynamics. There were concerns about how quickly the company could scale its operations and capture market share amidst increasing competition in the functional testing space.

Main topics on the call

• Strategic Shift to Precision Medicine — 2cureX is positioning itself to become a broader functional precision medicine platform, focusing on early diagnostics and personalized treatment options. Management stated, "we're really positioning ourselves to become ...
• Partnership with StorMyTumor — The partnership with StorMyTumor is expected to enhance patient testing options and expand operational capabilities in the U.S. market. Ole Thastrup noted, "this addition not just strengthens 2cureX as a company but it a...
• Regulatory Approvals and Competitive Advantage — 2cureX is set to be the first company with a functional test that has IVDR certification, providing a significant competitive edge. Thastrup mentioned, "we have a huge opportunity now that we will be IVDR certified being...
• Market Potential and Clinical Trials — Management highlighted the exponential growth in clinical trials for functional testing, indicating a favorable market environment. Hutley stated, "we're seeing an exponential growth in clinical trials in functional test...

Read the full 2cureX AB (publ) transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 2cureX AB (publ) earnings call transcripts on record, spanning November 15, 2022 to May 20, 2026. Based on this history, 2cureX AB (publ) reports semi-annually. The most recent call on file is dated May 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

2CUREX

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

10

First call

November 15, 2022

Most recent

May 20, 2026

Reporting cadence

semi-annually